Advertisement
Advertisement

BBIO

BBIO logo

BridgeBio Pharma, Inc. Common Stock

68.13
USD
Sponsored
+4.40
+6.90%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

68.34

+0.21
+0.31%

BBIO Earnings Reports

Positive Surprise Ratio

BBIO beat 8 of 26 last estimates.

31%

Next Report

Date of Next Report
Feb 19, 2026
Estimate for Q4 25 (Revenue/ EPS)
$148.42M
/
-$0.73
Implied change from Q3 25 (Revenue/ EPS)
+22.97%
/
-23.16%
Implied change from Q4 24 (Revenue/ EPS)
+2423.33%
/
-47.86%

BridgeBio Pharma, Inc. Common Stock earnings per share and revenue

On Oct 29, 2025, BBIO reported earnings of -0.95 USD per share (EPS) for Q3 25, missing the estimate of -0.90 USD, resulting in a -4.81% surprise. Revenue reached 120.70 million, compared to an expected 108.51 million, with a 11.23% difference. The market reacted with a -4.88% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 17 analysts forecast an EPS of -0.73 USD, with revenue projected to reach 148.42 million USD, implying an decrease of -23.16% EPS, and increase of 22.97% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Teva Pharmaceutical Industries Limited - ADR
Report Date
Jan 28, 2026 For Q4 25
Estimate
$0.69
Actual
$0.96
Surprise
+38.55%
FAQ
For Q3 2025, BridgeBio Pharma, Inc. Common Stock reported EPS of -$0.95, missing estimates by -4.81%, and revenue of $120.70M, 11.23% above expectations.
The stock price moved down -4.88%, changed from $66.62 before the earnings release to $63.37 the day after.
The next earning report is scheduled for Feb 19, 2026.
Based on 17 analysts, BridgeBio Pharma, Inc. Common Stock is expected to report EPS of -$0.73 and revenue of $148.42M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement